Brief: Hepion Pharmaceuticals Says Rencofilstat, In Combination With An Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity In A Nonclinical Liver Cancer Study
26/01/2022 13:46
Jan 26 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS’ RENCOFILSTAT, IN COMBINATION WITH
AN
IMMUNE CHECKPOINT INHIBITOR, DEMONSTRATES SYNERGISTIC ANTI-TUMOR
ACTIVITY IN A NONCLINICAL LIVER CANCER STUDY
Source text for Eikon: ID:nGNXbnQkTC
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement